Literature DB >> 12641370

Treatment of delirium in older adults with quetiapine.

Kye Y Kim1, Geoffrey M Bader, Victor Kotlyar, Debra Gropper.   

Abstract

Delirium is a neuropsychiatric syndrome characterized by impairment of consciousness, changes in cognition, or perceptual disturbances. In addition, delirium is often accompanied by delusions, hallucinations, and agitation. In this study, 12 older patients with delirium were treated for neuropsychiatric symptoms with quetiapine. The mean duration for stabilization was 5.91 +/- 2.22 days, and the mean dose was 93.75 +/- 23.31 mg/day. None of the 12 patients developed extrapyramidal symptoms. There were significant improvements on all measures used in this study. Interestingly, the Delirium Rating Scale scores along with scores of the Mini-Mental State Examination and Clock Drawing Test continued to improve throughout the 3-month study period. In our study, we found that quetiapine was a safe and effective treatment in hospitalized older patients with delirium.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12641370     DOI: 10.1177/0891988702250533

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  14 in total

Review 1.  Delirium: where do we stand?

Authors:  Chi-Un Pae; David M Marks; Changsu Han; Ashwin A Patkar; Prakash Masand
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

Review 2.  Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development.

Authors:  Shirley H Bush; Salmaan Kanji; José L Pereira; Daniel H J Davis; David C Currow; David Meagher; Kiran Rabheru; David Wright; Eduardo Bruera; Michael Hartwick; Pierre R Gagnon; Bruno Gagnon; William Breitbart; Laura Regnier; Peter G Lawlor
Journal:  J Pain Symptom Manage       Date:  2014-01-28       Impact factor: 3.612

Review 3.  Delirium in the older emergency department patient: a quiet epidemic.

Authors:  Jin H Han; Amanda Wilson; E Wesley Ely
Journal:  Emerg Med Clin North Am       Date:  2010-08       Impact factor: 2.264

Review 4.  Evidence-based treatment of delirium in patients with cancer.

Authors:  William Breitbart; Yesne Alici
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

5.  Delirium: underrecognized and undertreated.

Authors:  Chi-Un Pae; David M Marks; Changsu Han; Ashwin A Patkar; Prakash Masand
Journal:  Curr Treat Options Neurol       Date:  2008-09       Impact factor: 3.598

6.  Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options.

Authors:  Joseph D Markowitz; Meera Narasimhan
Journal:  Psychiatry (Edgmont)       Date:  2008-10

7.  Quetiapine in refractory hyperactive and mixed intensive care delirium: a case series.

Authors:  Ruth Y Y Wan; Moneesha Kasliwal; Catherine A McKenzie; Nicholas A Barrett
Journal:  Crit Care       Date:  2011-06-28       Impact factor: 9.097

Review 8.  Antipsychotics for treatment of delirium in hospitalised non-ICU patients.

Authors:  Lisa Burry; Sangeeta Mehta; Marc M Perreault; Jay S Luxenberg; Najma Siddiqi; Brian Hutton; Dean A Fergusson; Chaim Bell; Louise Rose
Journal:  Cochrane Database Syst Rev       Date:  2018-06-18

9.  Quetiapine Sustained Release in Treatment of Delirium Induced by Cerebral Metastasis.

Authors:  Antonino Messina; Anna Maria Fogliani
Journal:  Case Rep Oncol       Date:  2010-07-16

10.  Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial.

Authors:  Benchalak Maneeton; Narong Maneeton; Manit Srisurapanont; Kaweesak Chittawatanarat
Journal:  Drug Des Devel Ther       Date:  2013-07-24       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.